Suppression of Erosive Arthritis by NF-κB Inhibitors

Title: Suppression of Erosive Arthritis by NF-κB Inhibitors

Volume: 7 Issue: 4

Author(s): Tetsuo Kubota and Kazuo Umezawa

Affiliation:

Keywords: NF-kappa B, DHMEQ, macrophage, osteoclast, NFATc1, chemotherapy

Abstract: Excess activation of NF-kappa B is often involved in inflammation and cancer progression. We have developed a specific NF-kappa B inhibitor dehydroxyepoxyquinomicin (DHMEQ). It binds to the specific cysteine residue of Rel family proteins. DHMEQ inhibited cytokine secretions and osteoclastogenesis in cultured macrophages. It inhibited various animal models of inflammation and cancer. Especially, it inhibited type 2-induced rheumatoid arthritis without any toxicity in mice. It also decreased the number of osteoclasts in the inflammatory tissues. Thus, excess activation of NF-kappa B is essential for rheumatoid arthritis, and DHMEQ is a candidate of new anti-rheumatoid chemotherapeutic agent.

Cite this article as:

Kubota Tetsuo and Umezawa Kazuo, Suppression of Erosive Arthritis by NF-κB Inhibitors, Current Rheumatology Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339711798221077

DOI https://dx.doi.org/10.2174/157339711798221077	Print ISSN 1573-3971
Publisher Name Bentham Science Publisher	Online ISSN 1875-6360